Kindred Biosciences, Inc.
KIN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for KIN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2021.
Run Kindred Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Kindred Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
84.3 months
D/E 0.36
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Governance
Frequently asked questions
Who is the CEO of Kindred Biosciences, Inc.?
Richard Chin, M.D. is the chief executive officer of Kindred Biosciences, Inc. (KIN).
What therapeutic areas does Kindred Biosciences, Inc. focus on?
Kindred Biosciences, Inc. develops therapies across Immunology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.